Press release Communiqué de presse

Share the news     Partagez les nouvelles

Press release Communiqué de presse

May 4, 2018 4 May, 2018

Sernova Announces Results of 2018 Annual General Meeting of Shareholders and New Chief Financial Officer

Shareholder approval of all management resolutions at AGM; CEO announces new Biotech CFO with strong North America capital market experience

Source: Sernova Corp

May 4, 2018, 6:00 a.m. EDT

LONDON, ONTARIO – (Globe Newswire – May 4, 2018) – Sernova Corp. (TSX-V: SVA) (OTCQB: SEOVF) (FSE: PSH), announced shareholder approval of all management resolutions brought forward at the 2018 Annual General Meeting held in Vancouver, April 25th. In addition, we are pleased to announce Mr. Sean Hodgins, CA, CPA, CPA (Illinois) has joined Sernova as Chief Financial Officer, effective immediately. Mr. Hodgins will work in conjunction with Sernova’s CEO in the execution of the company’s financial, business development and capital markets strategies as well as future planned tracking to a US exchange.

“Mr. Hodgins is an experienced biotech executive with both US and Canada corporate background. He is joining Sernova at an important juncture as we embark on our US clinical study and further develop our international business relationships,” said Dr. Philip Toleikis, President and CEO, Sernova Corp.

A veteran of the biotechnology industry for over 20 years, Mr. Hodgins is a CA-CPA having earned a Bachelor of Commerce degree (economics) from the University of British Columbia. He has gained US and Canada experience having tenured at Deloitte LLP in Vancouver and PricewaterhouseCoopers LLP in San Jose, California. While in the US he managed two NASDAQ IPO’s, and on returning to Canada, several Canadian IPOs as well as serving as CFO for three TSX listed public companies and supporting a number of successful Canadian biotech companies.

Sernova thanks Mr. Scott Langille for his contribution as previous CFO and wishes him well in his future endeavours.

Management resolutions at the AGM which were approved by an overwhelming majority of shareholders who voted including election of the directors, Frank Holler (chair), James Parsons, Bruce Weber, Jeffrey Bacha and Dr. Philip Toleikis; approval of the stock option plan and amendments and approval of Davidson and Co. LLP as Sernova’s auditor for 2019.

About Sernova Corp Sernova Corp is developing disruptive regenerative medical technologies using a medical device (Cell Pouch) and immune protected therapeutic cells to improve the treatment and quality of life of people with chronic metabolic diseases such as insulin- dependent diabetes, blood disorders including hemophilia, and other diseases treated through replacement of proteins or hormones missing or in short supply within the body. For more information, please visit www.sernova.com

For further information contact: Philip Toleikis, Ph.D., President and CEO Tel: (604) 961-2939; philip.toleikis@sernova.com www.sernova.com

Ray Matthews & Associates Tel: (604) 818-7778; www.raymatthews.ca ray@raymatthews.ca

Forward Looking Information This release may contain forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects”, “plans”, “anticipates”, “believes”, “intends”, “estimates”, “projects”, “potential” and similar expressions, or that events or conditions “will”, “would”, “may”, “could” or “should” occur. Although Sernova believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in forward looking statements. Forward-looking statements, are based on the beliefs, estimates and opinions of Sernova’s management on the date such statements were made, which include our belief about the conduct and outcome of clinical trials and that Sernova will be able to raise additional capital to fund its clinical programs including its planned US FDA clinical trial. Sernova expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.